Cargando…

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis

Brain metastases are especially common in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with a cumulative incidence of over 50% and associated with a poor prognosis, high symptom burden, and decreased quality of life. Lorlatinib is a brain-penetrant, third-generation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Geoffrey, Lam, Vincent K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499938/ https://www.ncbi.nlm.nih.gov/pubmed/37573276 http://dx.doi.org/10.1007/s12325-023-02606-x

Ejemplares similares

Podcast on the Management of Adverse Events Associated with Lorlatinib
por: Bauer, Todd M., et al.
Publicado: (2022)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
por: Zhou, Qing, et al.
Publicado: (2023)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

Refining precision cancer therapy in ALK-positive NSCLC
por: Lin, Jessica J., et al.
Publicado: (2019)

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement
por: Longo, Vito, et al.
Publicado: (2020)

First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely
por: Ivanyi, Philipp, et al.
Publicado: (2023)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
por: Ma, Xiya, et al.
Publicado: (2023)

Successful treatment of refractory brain metastases from ALK‐positive lung cancer with lorlatinib
por: Nakagawa, Yoshiko, et al.
Publicado: (2022)

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast]
por: Song, Eingun James, et al.
Publicado: (2023)

Genetic Testing in Metastatic Breast Cancer in the USA: A Podcast
por: Basho, Reva, et al.
Publicado: (2023)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
por: Feng, Xu, et al.
Publicado: (2021)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

HGG-08. Lorlatinib for the treatment of ALK fusion positive infant high grade glioma
por: Greenwell, Alyssa, et al.
Publicado: (2022)

Lorlatinib for ALK‐fused, infant‐type hemispheric glioma with lung metastasis: a case report
por: Lai, Mingyao, et al.
Publicado: (2023)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Biomarker Testing for Actionable Alterations in NSCLC—Perspectives from US-Based Academic and Community Oncologists: A Podcast
por: Iams, Wade T., et al.
Publicado: (2023)

The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden
por: Naik, Jaesh, et al.
Publicado: (2023)

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
por: Li, Huihui, et al.
Publicado: (2023)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Lorlatinib Therapy for Rapid and Dramatic Control of Brain and Spinal Leptomeningeal Metastases From ALK-Positive Lung Adenocarcinoma
por: Sun, Min-Gwan, et al.
Publicado: (2021)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu, Viola W, et al.
Publicado: (2020)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
por: Patel, Sandip, et al.
Publicado: (2023)

EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
por: Matsuda, Hironari, et al.
Publicado: (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_234edhb57juof6jhghl2dk1rs0